Request a Proposal
Welcome to Rapport, containing tips, truths, news and views, blogs, tweets, articles and films covering a range of topics currently affecting Research Partnership and the pharma market research world.
  • Posted by Paul Reed
  • October 1, 2018
  • Articles

Dónde estoy, onde estou, où suis-je, where am I?

Dónde estoy, onde estou, où suis-je, where am I?

Defining the regions of Latin America and the Caribbean

Although we have conducted a lot of research studies in Latin America and the Caribbean, we couldn’t, as a team, agree exactly what defines this region and its boundaries for our clients. This is because our clients structure their LATC divisions in different ways. They often decide how to structure themselves based on where the best talent is located within the region and then balance that against proximity to strategic regions and US offices.  As a result LATC operational teams vary by organisation. There is no standard blue print.

read more »

A common reality: How augmented reality is transforming the future of pharmaceutical marketing

A common reality: How augmented reality is transforming the future of pharmaceutical marketing

In the second installment of a three-part series exploring virtual and augmented reality, Harrison Gaiger explores the ways in which augmented reality is transforming the future of pharmaceutical marketing.

In a previous article I explored the growing role that Virtual Reality (VR) is playing in the healthcare industry, including its use as a marketing tool for pharmaceutical companies, and questioned what the future of VR may look like in a world where technological advancements are being made every day. It seemed clear to me that while VR is still in the early stages of medical application, it’s already making a huge impact on the healthcare industry and that, regardless of its infancy, VR technology is most likely here to stay. Because of this I concluded by saying that tech-savvy pharmaceutical marketers should consider adding it to their future strategies as an invaluable means for engaging with customers. In the second instalment of this three-part series, I look at the ways in which Augmented Reality (AR) is transforming the future of pharmaceutical marketing.

read more »

  • Posted by Marc Yates
  • September 20, 2018
  • Articles

Comparing apples and oranges: Is a global segmentation transferable?

Comparing apples and oranges: Is a global segmentation transferable?

When our clients are considering primary market research in emerging markets they typically face two challenges - a lack of good local data and budget.

The absence of reliable and up-to-date information in emerging markets should mean that a greater budget is allocated to primary market research. However, in reality the opposite is true. Consequently, our clients want to know if they can tailor global studies to reflect the nuances of different emerging markets.

read more »

Game changer? The role of virtual reality in healthcare

Game changer? The role of virtual reality in healthcare

In the first of a series of articles exploring virtual and augmented reality, Harrison Gaiger outlines the medical applications of VR and how pharma can leverage this innovative technology in the future.

The next decade promises to be an exciting time for science and innovation. Technological advancements are being made on a daily basis and many of these have the potential to directly impact our everyday lives. In fact, technology is changing at such a rate that it can often seem difficult to keep up. One technological advancement with the potential to change how we interact with technology and each other is Virtual Reality (VR) – immersive computer-generated environments that place users in seemingly life-like situations with which they can interact. VR, once the stuff of science-fiction, is now becoming a viable mainstream product.

read more »

  • Posted by Helen Parfitt
  • August 24, 2018
  • Articles

JAK inhibitors gaining traction for rheumatoid arthritis in EU5

JAK inhibitors gaining traction for rheumatoid arthritis in EU5

The new class of JAK inhibitor therapies is making a strong impression in the European market for rheumatoid arthritis (RA), according to recent prescribing data from specialist physicians.
Our latest Therapy Watch RA study, conducted in the key EU5 countries (France, Germany, Italy, Spain and the UK), found that in the dynamic segment of the RA market – defined as patients who have started or switched onto their current RA treatment in the three months preceding inclusion in the study – the orally -administered JAK inhibitors expanded their market share across the EU5 from 3.1% in the third quarter of 2017 to 15.6% in the second quarter of 2018.

read more »